InnovHeart is a developer of transcatheter mitral valve replacement systems to treat patients suffering from mitral valve disease.
InnovHeart has raised $55.0M in total funding. The most recent round was Series C. The last funding was announced in January 2022.
InnovHeart's investors include CDP Venture Capital, Indaco Venture Partners, Panakes Partners, Genextra, China Grand Pharmaceutical and Healthcare Holdings.
InnovHeart is headquartered in Milano, Italy.
InnovHeart is a developer of transcatheter mitral valve replacement systems to treat patients suffering from mitral valve disease.
InnovHeart is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"InnovHeart — Funding & Investors." VCBacked, January 27, 2022, https://www.vcbacked.co/company/innovheart. Accessed July 19, 2026.
VCBacked. (2022). InnovHeart — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/innovheart
{{cite web |title=InnovHeart — Funding & Investors |url=https://www.vcbacked.co/company/innovheart |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated